ArticleCancers2021
The Impact of Multidisciplinary Team Meetings on Patient Management in Oncologic Thoracic Surgery: A Single-Center Experience.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumour boards and their quality of structures, processes, and team performance in multidisciplinary cancer care: a systematic review.BMC health services research · 2026Pooled it
- Multidisciplinary Decision-Making and Integrated Strategies in Stage III Non-Small Cell Lung Cancer: Exploring Clinical Reasoning in Therapeutic Choices.Journal of clinical medicine · 2026Article
- Giant paraganglioma: A successful multidisciplinary approach.Journal of vascular surgery cases and innovative techniques · 2025Article
- Importance of the multidisciplinary approach in the surgical treatment of giant mediastinal neoplasms: a case series.AME case reports · 2025Article
- Analysis of the Results of Monitoring the Quality of Services in Oncological Treatment, Conducted as Part of the Pilot Project of the National Cancer Network for Lung Cancer in 2019-2023, in Poland.Patient preference and adherence · 2025Article
- Stage I and II nonsmall cell lung cancer treatment options.Breathe (Sheffield, England) · 2024Review
- Review
- Body CT examinations in oncologic patients: the impact of subspecialty radiology on radiation exposure in the clinical practice. A quality care study.La Radiologia medica · 2024Article
- Concurrent squamous cell carcinoma and non-hodgkin lymphoma: a rare case report and multidisciplinary approach.Case reports in plastic surgery & hand surgery · 2024Article
- Article
- State of the art and new perspectives in surgical treatment of lung cancer: a narrative review.Translational cancer research · 2022Review
- The Role of Surgery in High-Grade Neuroendocrine Cancer: Indications for Clinical Practice.Frontiers in medicine · 2022Review
- Do oncologists prefer subspecialty radiology reports? A quality care study.Insights into imaging · 2021Article
- Prognostic Value of the Hemoglobin/Red Cell Distribution Width Ratio in Resected Lung Adenocarcinoma.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundthe aim of this paper is to quantify multidisciplinary team meeting (MDT) impact on the decisional clinical pathway of thoracic cancer patients, assessing the modification rate of the initial out-patient evaluation.
methodsthe impact of MDT was classified as follows: confirmation: same conclusions as out-patient hypothesis; modification: change of out-patient hypothesis; implementation: definition of a clear clinical track/conclusion for patients that did not receive any clinical hypothesis; further exams required: the findings that emerged in the MDT meeting require further exams.
resultsone thousand consecutive patients evaluated at MDT meetings were enrolled. Clinical settings of patients were: early stage lung cancer (17.4%); locally advanced lung cancer (27.4%); stage IV lung cancer (9.8%); mesothelioma (1%); metastases to the lung from other primary tumors (4%); histologically proven or suspected recurrence from previous lung cancer (15%); solitary pulmonary nodule (19.2%); mediastinal tumors (3.4%); other settings (2.8%).
conclusionsMDT meetings impact patient management in oncologic thoracic surgery by modifying the out-patient clinical hypothesis in 10.6% of cases; the clinical settings with the highest decisional modification rates are "solitary pulmonary nodule" and "proven or suspected recurrence" with modification rates of 14.6% and 13.3%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.